PAVBLU
PAVBLU (aflibercept-ayyh) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of several serious retinal conditions. It is used to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema. The drug is also approved for the treatment of patients with diabetic retinopathy. As a therapeutic agent, it addresses pathologies characterized by abnormal blood vessel growth and vascular permeability in the eye.
How PAVBLU Works
PAVBLU functions as a soluble decoy receptor that binds to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF). By capturing these growth factors, the drug prevents them from binding to and activating their cognate receptors, VEGFR-1 and VEGFR-2, on the surface of endothelial cells. This inhibition interrupts the signaling pathways that lead to neovascularization and increased vascular permeability. Consequently, the drug helps manage the biological processes that drive the progression of various retinal vascular diseases.
Details
- Status
- Prescription
- First Approved
- 2024-08-23
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
PAVBLU Approval History
What PAVBLU Treats
5 indicationsPAVBLU is approved for 5 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
PAVBLU Target & Pathway
ProTarget
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pathway Context
VEGFR on blood vessels is activated by VEGF to promote angiogenesis
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
PAVBLU is a lower-cost alternative to Eylea with no clinically meaningful differences. Requires prescriber approval to substitute.
PAVBLU Competitors
Pro2 other drugs also target VEGFR. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGFR). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to PAVBLU
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PAVBLU FDA Label Details
ProIndications & Usage
FDA Label (PDF)PAVBLU is indicated for the treatment of: PAVBLU is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.